

)' !%) %!\$%

U # V .
) V .
O V .
O V 'U U 'U # .

From: [Hanson, Latischa](#)
To: [Hill, Carol](#)
Subject: FW: Re: Dr. Sabbah/Maui Memorial
Date: Monday, July 18, 2022 6:33:37 AM
Attachments: [RAML Amendment 86. 12-16-2021\(1\).pdf](#)

Can you intake this & assign to me so I can get it done for him please? Thanks

Latischa

From: Ronald Frick <rfrick@gammamedphys.com>
Sent: Thursday, July 14, 2022 7:22 PM
To: Hanson, Latischa <Latischa.Hanson@nrc.gov>
Subject: [External_Sender] Re: Dr. Sabbah/Maui Memorial

Attached is a previous license authorizing him for I-131. Can you issue the amendment with I-131 and parenteral?

From: Hanson, Latischa <Latischa.Hanson@nrc.gov>
Sent: Thursday, July 14, 2022 1:49 PM
To: Ronald Frick <rfrick@gammamedphys.com>
Subject: RE: Dr. Sabbah/Maui Memorial

I could only approve him for parenteral. The I-131 was out of the 7 year recentness of training. If there is recentness documentation, you can resend in as another amendment request.

From: Ronald Frick <rfrick@gammamedphys.com>
Sent: Thursday, July 14, 2022 6:39 PM
To: Hanson, Latischa <Latischa.Hanson@nrc.gov>
Subject: [External_Sender] Dr. Sabbah/Maui Memorial

Hi Latischa,

I had forgotten about the voice mail you left previously, but was reminded when I saw your other email today. What is the issue with Dr. Sabbah? Did notice there are two different pages of 3.c training which covered I-131 and parenteral? Let me know what else you need.

Thanks,

Ron Frick

RADIOACTIVE MATERIAL LICENSE

Pursuant to the California Code of Regulations, Division 1, Title 17, Chapter 5, Subchapter 4, Group 2, Licensing of Radioactive Material, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, use, possess, transfer, or dispose of radioactive material listed below; and to use such radioactive material for the purpose(s) and at the place(s) designated below. This license is subject to all applicable rules, regulations, and orders of the California Department of Public Health now or hereafter in effect and to any standard or specific condition specified in this license.

1. Licensee:	Antelope Valley Hospital	3. License Number:	1365-19	Amendment Number:	86
2. Address:	1600 West Avenue J Lancaster, CA 93534	4. Expiration date:	April 12, 2024		(3)
Attention:	Ashley C. Cagalawan, CNMT Nuclear Medicine Supervisor	5. Inspection agency:	Los Angeles County		

In response to the letter, with attachment, received November 12, 2021, signed by Kory Kodimer, Ph.D., Radiation Safety Officer, License Number 1365-19 is hereby amended as follows:

6. Nuclide	7. Form	8. Possession Limit
A. Any radioactive material permitted by 10 CFR 35.100, 35.200 and 35.300.	A. Any Excluding generators Excluding Xenon	A. Combined possession limit not to exceed 34.0 GBq (920 mCi).
B. 1. Any radionuclide with atomic numbers 3-83, inclusive, except: Strontium-90 and Lead-210. 2. Gadolinium-153 3. Strontium-90	B. 1. Sealed, solid or liquid sources manufactured in accordance with a specific license issued by the United States Nuclear Regulatory Commission, an Agreement State or a Licensing State. 2. Sealed sources (North American Scientific, Inc., Model MED 3601 and Isotope Product Laboratories. Models A3410 and NES 8412) 3. Applicator	B. 1. Total not to exceed 2.8 GBq (75 mCi). Each source not to exceed 740.0 MBq (20 mCi). 2. Total 37.0 MBq (1 mCi), no single source to exceed 18.5 MBq (500 microcurie). 3. Total 2.2 GBq (60 mCi) in 1 source.

9. Authorized Use

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
Any imaging and localization study permitted by 10 CFR 35.200.
Any use permitted by 10 CFR 35.300.
- B. 1. Marker and calibration sources.
2. Storage only.
3. Storage only.

RADIOACTIVE MATERIAL LICENSE

License Number: 1365-19
Amendment Number: 86

LICENSE CONDITIONS

10. Radioactive material shall be used only at the following location:
- (a) 1600 West Avenue J, Lancaster, CA.
11. This license is subject to an annual fee for sources of radioactive material authorized to be possessed at any one time as specified in Items 6, 7, 8 and 9 of this license. The annual fee for this license is required by and computed in accordance with Title 17, California Code of Regulations, Sections 30230-30232 and is also subject to an annual cost-of-living adjustment pursuant to Section 100425 of the California Health and Safety Code.
12. The individuals named below are authorized the specific uses of radioactive material described in Items 6, 7, 8, and 9 of this license as follows:
- (a) Andrew L. Deutsch, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (b) Gilbert Melin, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (c) Kevin M. Rice, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (d) Mark J. Beller, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (e) Jennifer A. Hill, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (f) David C. Lask, M.D.

35.100; 35.200; 35.300 excluding oral administration of sodium iodide I-131 in quantities greater than 33 millicuries and 9.C.1.
- (g) John B. Holden, M.D.

35.100; 35.200; 35.300 excluding oral administration of sodium iodide I-131 in quantities greater than 33 millicuries and 9.C.1.
- (h) Olga Lyass, M.D.

35.100; 35.200; 35.300 and 9.C.1.
- (i) Alma G. Loya, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (j) Vu L. Bui, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (k) Marcelo Spector, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (l) Paul Nabeel Mogannam, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (m) Karin L. Fu, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (n) Rajiv P. Pai, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (o) Lori Taylor, M.D.

35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 for imaging and localization studies only and 9.C.1.
- (p) Khalid Kurbanali Javeri, M.D.

35.100; 35.200 and 9.C.1.

RADIOACTIVE MATERIAL LICENSELicense Number: 1365-19Amendment Number: 86

- (q) Tomer Abraham Roth, M.D. 35.100; 35.200 and 9.C.1.
 - (r) Michael Zaghi, M.D. 35.100; 35.200 and 9.C.1.
 - (s) Ali Golshan, M.D. 35.100; 35.200 and 9.C.1.
 - (t) **Nathanael Sabbah, M.D. 35.100; 35.200; 35.300 for oral administration of sodium iodide I-131 and 9.C.1.**
13. Except as specifically provided otherwise by this license, the licensee shall possess and use radioactive material described in Items 6, 7, 8 and 9 of this license in accordance with the statements, representations, and procedures contained in the documents listed below. The Department's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- (a) The renewal application, with attachments, dated March 6, 2007, signed by Les Wong, Chief Executive Officer, supplemented by the letter, with attachments, dated October 2, 2013, signed by Kory Kodimer, Ph.D., Radiation Safety Officer.
14. (a) The Radiation Safety Officer in this program shall be Kory Kodimer, Ph.D.
(b) The Chairperson of the Radiation Safety Committee shall be Kory Kodimer, Ph.D.
15. Sealed sources possessed under this license shall be tested for leakage and/or contamination as required by Title 17, California Code of Regulations, Section 30275 (c).
16. In lieu of the leak test intervals required by California Code of Regulations, Title 17, Section 30275 (c), sealed sources can be tested for leakage and/or contamination at longer intervals when they are specified in a certificate of registration issued by the U.S. Nuclear Regulatory Commission, an Agreement State or a Licensing State. When a longer interval stipulated in a certificate of registration is used, the certificate must be maintained on file and available for inspection for as long as the associated leak test records are retained.
17. Quantitative analytical assays for the purpose of tests for leakage and/or contamination of sealed sources shall be performed only by persons specifically authorized to perform that service.
18. The following individuals are authorized to collect wipe test samples of sealed sources possessed under this license using leak test kits acceptable to the California Department of Public Health:
- (a) The Radiation Safety Officer
 - (b) Qualified individuals designated in writing by the Radiation Safety Officer
19. Except for alpha sources, the periodic leak test required by Condition 15 does not apply to sealed sources that are stored and not being used. The sources excepted from this test shall be tested for leakage prior to any use or transfer to another person unless they have been leak tested within six months prior to the date of use or transfer.
20. The licensee shall conduct a physical inventory every six months to account for all sealed sources and/or devices received and possessed under the license. Records of the inventories shall be maintained for inspection, and may be disposed of following Department inspection.
21. The licensee is authorized to hold radioactive materials with a physical half-life of less than 65 days including Co-57 for decay in storage before disposal in ordinary trash provided:
- (a) Radioactive waste to be disposed of in this manner shall be held for decay in storage for at least 10 half-lives. Co-57 shall be held for decay for at least 15 half-lives.

RADIOACTIVE MATERIAL LICENSELicense Number: 1365-19Amendment Number: 86

- (b) Before disposal as normal waste, radioactive waste shall be surveyed to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.
 - (c) Records shall be maintained of the disposal of licensed materials made by decay in storage. These records shall be sufficient to demonstrate compliance with this license condition and shall be retained for 3 years after the record is made.
22. The licensee may use one constancy source for the dose calibrator constancy test provided that the dose calibrator manual indicates that only one constancy source is needed for proper Quality Control.
23. Nuclear medicine technology procedures shall be performed by nuclear medicine technologists pursuant to Title 17, California Code of Regulations, Subchapter 4.7. Such procedures shall be performed under the supervision of authorized user physicians on this license who meet the criteria specified in Section 30510. Certificates or special permits issued pursuant to Subchapter 4.7 shall be prominently displayed at the facility authorized on this license.
24. Release of patients containing radioactive materials or implants containing radioactive materials shall be in accordance with 10 CFR 35.75 (1-1-13 Edition).
25. Production or processing of radiopharmaceuticals for the purpose of commercial distribution to other licensees is not authorized by this license.
26. For a period not to exceed 60 days in any calendar year, a physician is authorized to use licensed materials for human use under the terms of this license, provided the physician:
- (a) Has the prior written permission of the Licensee's Executive Management and its Radiation Safety Officer
 - (b) Is specifically named as an authorized user on a current and valid U.S. Nuclear Regulatory Commission, an Agreement State or a Licensing State license authorizing human use.
 - (c) Performs only those procedures for which the physician is specifically authorized by the U.S. Nuclear Regulatory Commission, an Agreement State or a Licensing State license.
- The licensee shall maintain for inspection copies of the written permission specified in (a) above and the licensee(s) specified in (b) and (c) above. These records shall be maintained for five years from the time the licensee grants its permission under (a) above.
27. When performing written directive procedures for administration of Iodine-131 greater than 30 microcuries and/or therapeutic procedures of both sealed or unsealed radioactive material the licensee must comply with the requirements listed in 10 CFR 35.41 (1-1-13 Edition) including, but not limited to, the following:
- (a) Develop, implement and maintain written procedures that ensure the following:
 - (1) The patient's or human research subject's identity is verified before each administration.
 - (2) Each administration is in accordance with the treatment plan, if applicable, and written directive.
 - (3) Both the manual and computer-generated dose calculations have been checked.
 - (b) Retain a copy of the written procedures for the duration of the license per 10 CFR 35.2041.
28. **In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material so that at no time will the total quantity of radioactive material possessed require financial surety for decommissioning in accordance with the California Code of Regulations, Title 17 (17 CCR), Section 30195.1. A value of 3.7 MBq (100 µCi) is assigned to cobalt-57 to supplement 17 CCR Section 30197.7.**

RADIOACTIVE MATERIAL LICENSELicense Number: 1365-19Amendment Number: 86

29. In accordance with California Health and Safety Code Section 115000.1(h), the licensee shall annually report the radioactive waste inventory held in storage on December 31 of each year and all manifests of Low Level Radioactive Waste (LLRW) shipments to licensed LLRW disposal facilities made during the year to the Department via the online LLRW Tracking System at <https://llrwts.cdph.ca.gov/>.
30. At least 30 days prior to vacating any address of use listed in Condition 10 of this license, the licensee shall provide written notification of intent to vacate to the California Department of Public Health, in accordance with Title 17, California Code of Regulations, Section 30256 (b). Control of all licensed areas must be maintained until such areas are released by the Department for unrestricted use or the license is terminated, in accordance with Title 17, California Code of Regulations, Section 30256 (j).
31. A copy of this license and a copy of all records and documents pertaining to this license shall be maintained available for inspection at 1600 West Avenue J, Lancaster, CA.

Issued for the State of California Department of Public HealthDate: December 8, 2021By: 

Radiologic Health Branch
MS 7610, P.O. Box 997414
Sacramento, CA 95899-7414

BETWEEN:

Accounts Receivable/Payable
and
Regional Licensing Branches

[FOR ARPB USE]
INFORMATION FROM WBL

Program Code: 02120
Status Code: Pending Amendment
Fee Category: 7C
Exp. Date: 01/31/2037
Fee Comments:
Decom Fin Assur Req'd: N

License Fee Worksheet - License Fee Transmittal

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: Maui Memorial Medical Center
Received Date: 07/18/2022
Docket Number: 3003561
Mail Control Number: 631863
License Number: 53-13519-01
Action Type: Amendment

2. FEE ATTACHED

Amount: N/A

Check No.: N/A

3. COMMENTS

Signed: Carol L. Hill

Date: 07/18/2022

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / /)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:

Amendment: _____

Renewal: _____

License: _____

3. OTHER _____

Signed: _____

Date: _____

Agency: NRC

WBL WORKSHEET

DOCKET NUMBER: 3003561	LICENSE NUMBER: 53-13519-01	STATUS: Pending Amendment
MAIL CONTROL NUMBER: 631863	RECEIPT DATE: 07/18/2022	ACTION TYPE: Amendment
DUE DATE: 10/16/2022	INST. CODE: 13519	LICENSE REGION: Region 4
LICENSE TYPE: 30	ENTITY TYPE: C	LICENSE GROUP: Medical
ISSUE DATE:	ORIGINAL DATE: 04/23/1991	EXPIRATION DATE: 01/31/2037
DECOMMISSIONING CATEGORY: Group 1	LAST ISSUE DATE:	
LICENSEE NAME: Maui Memorial Medical Center	DECOM FIN ASSUR REQD: N SUBM: N	
MAILING ADDRESS LINE1: 221 Mahalani Street	CONT PLAN REQD: N APPRV: N	
MAILING ADDRESS LINE 2:		
CITY: Wailuku	STATE: HI	ZIP: 96793
CONTACT PERSON: PREFIX:	FIRST NAME: Michael	MIDDLE INITIAL:
LAST NAME: Rembis	SUFFIX: FACHE	
JOB TITLE: CEO and Hospital Administrator	PHONE: 808-244-9056	FAX: 808-242-2443
EMAIL:		
BILLING ADDRESS LINE 1:		
BILLING ADDRESS LINE 2:		
CITY:	STATE: Hawaii	ZIP:
BILLING CONTACT PERSON: FIRST NAME:	MIDDLE INITIAL:	LAST NAME:
PHONE:	EMAIL:	FAX:
PRIMARY PGM CODE: 02120	SECONDARY PGM CODE:	
INSPECTION REGION: Region 4	PRIORITY: 3	
RSO: PREFIX:	FIRST NAME: Ronald	MIDDLE INITIAL: LAST NAME Frick
SUFFIX: M.S, CHP, DABR	RSO JOB TITLE: Radiation Safety Officer	
RSO PHONE: 808-373-7009	RSO FAX: 808-373-7017	RSO EMAIL: rflick@gammacorp.com
STATES WHERE USE IS AUTHORIZED: 1	0- ALL LISTED STATES 1- SAME AS STATE IN ADDRESS 2- ALL STATES 3- NON-AGREEMENT-STATES	
AUTHORIZED STATES (USE ONLY IF ABOVE IS ZERO):		



ACKNOWLEDGEMENT - RECEIPT OF CORRESPONDENCE

Name and Address of Applicant and/or Licensee

Michael Rembis
Chief Executive Officer
Maui Memorial Medical Center
221 Mahalani Street
Wailuku, HI 96793

Date

07/18/2022

License Number(s)

53-13519-01

Mail Control Number(s)

631863

Licensing and/or Technical Reviewer or Branch

C. Hill

This is to acknowledge receipt of your: ☒ Letter and/or ☐ Application Dated: 07/18/2022

The initial processing, which included an administrative review, has been performed.

☒ Amendment ☐ Termination ☐ New License ☐ Renewal

☐ There were no administrative omissions identified during our initial review.

☐ This is to acknowledge receipt of your application for renewal of the material(s) license identified above. Your application is deemed timely filed, and accordingly, the license will not expire until final action has been taken by this office.

☐ Your application for a new NRC license did not include your taxpayer identification number. Please complete and submit NRC Form 531, Request for Taxpayer Identification Number, located at the following link: <http://www.nrc.gov/reading-rm/doc-collections/forms/nrc531.pdf>
Follow the instructions on the form for submission.

☐ The following administrative omissions have been identified:

Your application has been assigned the above listed MAIL CONTROL NUMBER. When calling to inquire about this action, please refer to this control number. Your application has been forwarded to a technical reviewer. Please note that the technical review, which is normally completed within 180 days for a renewal application (90 days for all other requests), may identify additional omissions or require additional information. If you have any questions concerning the processing of your application, our contact information is listed below:

Region IV
U. S. Nuclear Regulatory Commission
DNMS/NMSB - B
1600 E. Lamar Boulevard
Arlington, TX 76011-4511
(817) 200-1103 or (817) 200-1140